medigraphic.com
Centro de Investigaciones Regionales Dr. Hideyo Noguchi, Universidad Autónoma de Yucatán

2009, Number 2

<< Back

Rev Biomed 2009; 20 (2)

Marijuana and the endocanabinoid system

Netzahualcoyotzi-Piedra C, Muñoz-Arenas G, Martínez-García I, Florán-Garduño B, Limón-Pérez ID

Language: Spanish
References: 110
Page: 128-153
PDF size: 485.19 Kb.


ABSTRACT

The use of hallucinogenic substances has being part of the human experience since ever in life. It is only now that a meticulous study of the active compound of these plants has gained major interest in those that are hallucinogenic and the consequences of their recreational use and their potential use as therapeutic. At present, we are still awaiting for results that will allow us to fully value the therapeutic effects that might be obtained by the rational use of the active compounds of the psychoactive plants. Marijuana has been stigmatized by the negative effects of its recreational use, though in traditional medicine it has been demonstrated a positive effect on the relief of various human sufferings. Because of that knowledge, we reviewed the recreational and therapeutic effects of Cannabis spp. We also described the endogenous system that recognizes the active principle of this plant: the endocannabinoid system. This system is widely distributed in the central nervous system and has drawn the at tention of investigators, whose recent studies are cited in this review. It has been shown that the endocannabinoid system plays an important role in neuromodulation of neurotransmitters such as γ-aminobutiric acid, glutamate and serotonin. On this way, the recently discovered endocannabinoid system would be an important pharmacological target and the therapeutic effects of Cannabis spp. is gaining confidence day by day.


REFERENCES

  1. Zuardi, AW. History of cannabis as a medicine: a review. Rev Bras. Psiquiatr 2006; 28(2):153-7.

  2. Hall W, Solowij N. Adverse effects of cannabis. Lancet 1998; 352:1611-15.

  3. Glockner J, Soto E, compiladores. La realidad alterada. Drogas, enteógenos y cultura. 1era ed. México (DF): Debate; 2006. pp. 96, 162-7.

  4. Childers SR, Breivogel CS. Cannabis and endogenous cannabinoid systems. Drug Alcohol Depend 1998; 51:173–87.

  5. Jimenez-Del-Rio M, Daza-Restrepo A, Velez-Pardo C. The cannabinoid CP55,940 prolongs survival and improves locomotor activity in Drosophila melanogaster against paraquat: Implications in Parkinson’s disease.Neurosci Res 2008; 61:404–11.

  6. Svíženská I, Dubový P, Šulcová A. Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures-A short review. Pharmacol Biochem Behav 2008; 90:501-11.

  7. Lorenzo P, Ladero JM, Leza JC, Lizasoain I. Drogodependencias: farmacología, patología, psicología, legislación. 2a ed. Madrid: Panamericana; 2003. p. 265.

  8. Ramos-Atance JA, Fernández-Ruiz J. Canabinoides: propiedades químicas. Monografía Cannabis. Adicciones 2000; 12 (sppl 2):41-58.

  9. Iversen, LL. The Science of Marijuana.1era ed. New York (NY): Oxford University Press; 2000. pp. 26, 5, 6, 172-4.

  10. Ramos-Atance JA, Fernández-Ruiz J. Uso de los canabinoides a través de la historia. Canabinoides: propiedades químicas. Monografía Cannabis. Adicciones 2000; 12 (sppl 2):19-30.

  11. INEGI, Instituto Nacional de Estadística, Geografía e Informática. Encuesta Nacional de Adicciones 2002 (ENA 2002). México.

  12. Iversen, LL. The science of marijuana. 1ra ed. New York (NY): Oxford University Press; 2000. p. 2.

  13. Turner CE, Elsohly MA, Boeren EG. Constituent of Cannabis sativa L. A review of the natural constituent.J Nat Prod 1989; 43:169-234.

  14. Dewey, WL. Cannabinoid Pharmacology. Pharmacol Rev 1986; 38: 151-78.

  15. Tsatsakis AM, Tutudaki M, Stiakakis I, Dimopoulou M, Tzatzarakis M, Michalodimitrakis M. Characterisation of cannabis plants phenotypes from illegal cultivations in Crete. Boll Chim Farm 2000; 139(sppl 3):140-5.

  16. Mechoulam R, Devane WA, Glaser R. Cannabinoid geometry and biological activity in marijuana/ Cannabinoids. En: Murphy L, Bartke A. Neurobiology and Neurophysiology. Boca Ratón, FL: CRC Press; 1992. p. 1-34.

  17. Condie R, Herring A, Koh WS, Lee M, Kaminski NE. Cannabinoid inhibition of adenylate cyclasemediated signal transduction and interleukin 2 (IL-2) expression in the murine T-cell line, EL4.IL-2. J Biol Chem 1996; 271:13175-83.

  18. Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG. Action of canabidiol on the anxiety and other effects produced by delta-9-THC in normal subjects. Psychopharmacology 1982; 76:245-50.

  19. Hampson AJ, Grimaldi M, Axelrod J, Wink D. Cannabidiol and (-)D9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA 1998; 95:8268-73.

  20. Makriyannis A, Yang DP, Griffin RG, Dasgupta SK. The pertubation of models membranes by (-)-delta-9- tetrahydrocannabinol into erythtocytes membranes in vivo and its effect on membrane fluidity. Experientia 1984; 40:866-8.

  21. Gill EW, Jones G. Brain levels of delta-1- tetrahydrocannabinol and its metabolites in mice correlation with behaviour and effect of the metabolic inhibitors SKF 525A and piperonyl butoxide. Biochem Pharmacol 1972; 21:2237-48.

  22. Harvey, DJ. Stability of cannabinoids in dried samples of cannabis dating from around 1986-1905. J Ethnopharmacol 1990; 28:117-28.

  23. Garret ER, Gouyette AJ, Roseboom H. Stability of tetrahydrocannabinols, II. J Pharm Sci 1978; 67:27- 32.

  24. Brailowsky S. Las Sustancias de los Sueños: Neuropsicofarmacología. 1ª edición. México: Fondo de Cultura Económica; 1995. p. 198-207.

  25. Lindgren JE, Ohlsson A, Agurell S, Hollister L, Gillespie H. Clinical effects and plasma levels of delta 9-tetrahydrocannabinol (delta 9-THC) in heavy and light users of cannabis. Psychopharmacology 1981; 74:208-12.

  26. Barnett G, Chiang CW, Perez-Reyes M, Owens SM. Kinetic study of smoking marihuana. J Pharmacokinetics Biopharmaceut 1982; 10:495-506.

  27. Hollister LE, Gillespie HK, Ohlsson A, Lindgren JE, Wahllen A, Agurell S. Do plasma concentrations of 9-tetrahydrocannabinol reflect the degree of intoxication? J Clin Pharmacol 1981; 21:171S-7S.

  28. Grotenhermen, F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 2003; 42:327-60.

  29. Pertwee RG, Gibson TM, Stevenson LA, Ross RA, Banner WK, Saha B, et al. O-1057, a potent water-soluble cannabinoid receptor agonist with antinociceptive properties. Br J Pharmacol 2000; 129: 577-84.

  30. Garret ER, Hunt CA. Pharmacokinetics of Δ-9-THC in dog. J Pharm Sci 1977; 66:395-407.

  31. Klausner HK, Wilcox HG, Dingell JV. The use of zonal centrifugation in the investigation of the binding of Δ-9-THC to plasma lipoproteins. Drug Metab Dispos 1975; 3:314-9.

  32. Monsalve C, Gomar C. Usos terapéuticos del cannabis. FMC 2000; 7:250-9.

  33. Ramos Atance JA, Fernández Ruiz J. Cannabinoides: propiedades químicas y aspectos metabólicos. Adicciones 2000; 12 (Suppl 2):41-56.

  34. Williamson EM, Evans F. Cannabinoids in clinical practice. Drugs 2000; 60:1303-14.

  35. Fernandez-Ruiz JJ, Rodríguez F, Navarro M,Ramos JA. Maternal cannabinoid exposure and brain development: changes in the ontogeny of dopamine neurons. En: Bartke A, Murphy LL. Neurobiology and neurophysiology of cannabinoids. Biochemistry and physiology of substance abuse. Boca Ratón, FL: CRC Press; 1992. p. 119-64.

  36. Burstein S., Kupfer D. Hydroxylation of transdelta- tetrahydrocannabinol by hepatic microsomal oxygenases. Ann NY Acad Sci 1971; 191:61-7.

  37. Bornheim LM, Lasker JM, Raucy JL. Human hepatic microsomal metabolism of delta-1- Tetrahydrocannabinol. Drug Mateb Dispos 1992; 20:241-6.

  38. Harvey DJ, Martin BR, Paton WDM. Identification of glucuronides as in vivo liver conjugates of seven cannabinois and some of their hydroxy and acid metabolites. Res Commun Chem Pathol Pharmacol 1977; 16:265-79.

  39. Leighty EG, Fentiman Jr. AF, Foltz RL. Long-retained metabolites of delta 8 and delta 9- tetrahydrocannabinol identified as novel fatty acid conjugates. Res Commun Chem Pathol pharmacol 1976; 14:13-28.

  40. Mecholuam, R. Cannabinoid chemistry. In Marihuana, Chemistry, Pharmacology, Metabolism and Clinical Effects. Academic, New York: p. 1-99.

  41. Harvey DJ. Metabolism and pharmacokinetics of the cannabinoids. Biochemistry and Physiology of substance abuse, CRC Press, Boca Raton, FL, p. 279- 365.

  42. Yamamoto I, Kuzuoka K, Watanabe k, Narimatsu S, Yoshimura H. Metabolic formation and pharmacological effects of 11-hydroxy-cannabinol. Marihuana: An Interdisciplinary Research Report. National Campaign Against Drug Abuse, Australian Government Printing Services, Canberra: p.135-40.

  43. Harvey DJ, Martin BR, Paton WDM. In vivo metabolism of cannabinol by the mouse and rat and a comparison with the metabolism of delta-9- tetrahydrocannabinol and cannabidiol. Biomed Mass Spectrom 1977; 4:364-70.

  44. Perez-Reyes M, Wall ME. Presence of delta 9-tetrahydrocannabinol in human milk. N Engl med 1982; 307:819-20.

  45. Pazos MR, Nuñez E, Benito C, Tolón RM, Romero J. Functional neuroanatomy of the endocannabinoid system. Pharmacol Biochem Behav 2005; 81:239-47.

  46. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, et al. Identification of an endogenous 2-monogliceryde, present in canine gut, that binds to canabinoid receptors. Biochem Pharmacol 1995; 50:83-90.

  47. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, et al. International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors. Pharmacological Reviews 2002; 54(Suppl 2): 161-202.

  48. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a Brain constituent that binds to the cannabinoid receptor. Science (1992); 258: 1946-1949.

  49. Piomelli, D. The molecular logic of endocannabinoid signaling. Nature Reviews Neuroscience 2003; 11:873-4.

  50. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365 (6441):12-3.

  51. Lunn, CA. A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo. J Pharmacol Exp Ther 2006; 316:780-8.

  52. Devane WA, Dyzarz FA, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988; 34:605-13.

  53. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346:561-4.

  54. Howlett, AC. The CB1 cannabinoid receptor in the Brain. Neurobiol Dis 1998; 5:405-6.

  55. Ishac EJ, Jiang L, Lake KD, Varga K, Abood ME, Kunus G. Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. Br J Pharmacol 1996; 118:2023-28.

  56. Herkenham M, Lynn AB, de Costa BR, Richfield EK. Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res 1991; 547:267- 74.

  57. Pertwee, RG. Pharmacology of cannabinoids CB1 and CB2 receptors. Pharmacol Ther 1997; 74:129-180.

  58. Herkenham M, Groen BGS, Lynn AB, de Costa BR,Richfield EK. Neuronal localization of cannabinoid receptors and second messengers in mutant mouse cerebellum. Brain Res 1991; 552: 301-10.

  59. Ho BY, Zhao J. Determination of the cannabinoid receptors in mouse x rat hybridoma NG108-15 cells and rat GH4C1 cells. Neurosci Lett 1996; 212:123-6.

  60. Felder CC, Briley EM, Axelrod J, Simpsom JT, Mackie K, Devane WA. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc Natl Acad Sci USA 1999.

  61. Bouaboula M, Poinot-Chazel C, Bourrié B, Canat X, Calandra B, Rinaldi-Carmona M, et al. Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem J 1995; 312: 637-41.

  62. Oviedo A, Glowa J, Herkenham M. Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study. Brain Res 1993; 616 293-302.

  63. Lastres-Becker I, Cebeira M, de Ceballos ML, Zeng BY, Jenner P, Ramos JA, et al. Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson´s syndrome and of MPTP-treated marmosets. Eur J Neurosc 2001; 14: 1827-32.

  64. Romero J, Berrendero F, Pérez-Rosado A, Manzanares J, Rojo A, Fernéndez-Ruiz JJ, et al. Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptors mRNAlevels in the caudate-putamen. Life.

  65. Pertwee RG, Wickens AP. Enhancement by chlordiazepoxide of catalepsy induced in rats by intravenous or intrapallidal injections of enantiomeric cannabinoids. Neuropharmacol 1991; 30: 237-44.

  66. Hillard CJ, Auchampach JA. In vitro activation of brain protein kinase C by the cannabinoids. Biochim Biophys Acta 1994; 1220: 163-70.

  67. Maneuf YP, Nash JE, Crossman AR, Brotchie JM. Activation of the cannabinoid receptor by Δ9- tetrahidrocannabinol reduces γ-aminobutyric acid uptake in the globus pallidus. Eur J Pharmacol 1996; 308:161-4.

  68. Mackie K. Cannabinoid receptor homo- and heterodimerization. Life Sci 2005; 77: 1667-73.

  69. Meschler JP, Howlett A. Signal transduction interactions between CB1 cannabinoid and dopamine receptors in the rat and monkey striatum. Neuropharmacol 2001; 40:918-26.

  70. Giuffrida A, Parsons LH, Kerr TM, Rodriguez de Fonseca F. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 1999; 2-4.

  71. Glass M, Felder CC. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: Evidence for a Gs linkage to the CB1 receptor. J Neurosci 1997; 17(sppl 14):5327-33.

  72. Floran B, Floran L, Sierra A, Aceves J. D2 receptormediated inhibition of GABA release by endogenous dopamine in the rat globus pallidus. Neurosci Lett 1997; 237:1-4.

  73. González B, Paz F, Florán L, Aceves J, Erlij D, Florán B. Cannabinoid agonist stimulate [3H]-GABA release in the globus pallidus of the rat when Gi Proteinreceptor coupling is restricted: Role of dopamine D2 receptors. J Pharmacol Exp Ther 2009; 32.

  74. Lepicier P, Bouchard JF, Lagneux C, Lamontagne D. Endocannabinoids protect the rat isolated heart against ischaemia. Br J Pharmacol 2003; 139:805-15.

  75. Núñez E, Benito C, Tolón RM, Hillard CJ, Griffin WST, Romero J. Glial expression of cannabinoid CB2 receptors and fatty acid amide hydrolase are beta amyloid-linked events in Down’s syndrome. Neurosci 2008; 151:104-10.

  76. Di-Marzo, V. Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discovery 2008; 7:438-55.

  77. Shire D, Calandra B, Rinaldi-Carmona M, Oustric D, Pessègue B, Bonnin-Cabanne O, et al. Molecular cloning, expression and function of murine CB2 peripheral cannabinoid receptor. Biochim Biophys Acta 1996; 1307:132-6.

  78. Schultes R, Hofmann A. Plantas de los dioses. 2a. ed. México: Fondo de cultura económica; 2000. p. 101.

  79. Pope HG, Yurgelun-Todd D. The residual cognitive effects of heavy marijuana use in college students. JAMA 1996; 272(Suppl 7):521-7.

  80. Ashton, CH. Adverse effects of cannabis and cannabinoids. Br J Anaesth 1999; 83:637-49.

  81. Thomas, H. Psychiatric symptoms in cannabis users. Brit J Psychiat 1993; 163:141-9.

  82. Jones RT. Marihuana: human effects. Handbook of Psychopharmacology 1978; 12:p. 373-412.

  83. Lichtman AH, Martin BR. Delta 9-tetrahydrocannabinol impairs spatial memory through a cannabinoid receptor mechanism. Psychopharmacology 1996; 126: 125-31.

  84. Katona I, Sperlagh B, Magloczky Z, et al. GABAergic interneurons are the targets of cannabinoid actions in the human hippocampus. Neuroscience 2000; 100: 797-804.

  85. Bohme GA, La Ville M, Ledent C, Parmentier M, Imperato A. Enhanced long term potentiation in mice lacking cannabinoid CB1 receptors. Neuroscience 2000; 95: 5-7.

  86. Reibaud M, Obinu MC, Ledent C, Parmentier M, Bohme GA, Imperato A. Enhancement of memory in cannabinoid CB1 receptor knockout mice. Eur J Pharmacol 1999; 379: R1-R2.

  87. Cimbura G, Lucas DM, Bennett RC, Donelson AC. Incidence and toxicological aspects of cannabis and ethanol detected in 1,394 fatally injured drivers and pedestrians in Ontario (1982-1984). J Forensic Sci 1990; 35:1035-41.

  88. Tashkin, DP. Pulmonary complications of smoked substance abuse. West J Med 1990; 152:525-30.

  89. Sridhar KS, Raub WA, Weatherby NL Jr. Possible role of marijuana smoking as a carcinogen in the development of lung cancer at a young age. Journal of Psychoactive Drugs 1994; 26(Suppl 3):285-8.

  90. Lee ML, Novotny M, Bartle KD. Gas chromatography/ mass spectrometric and nuclear magnetic resonance spectrometric studies of carcinogenic polynuclear aromatic hydrocarbons in tobacco and marijuana smoke condensates. Anal Chem 1976; 48 (sppl 2):405-1.

  91. Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE. Triggering myocardial infarction by marijuana. Circulation 2001; 103:2805-9.

  92. Polen MR, Sidney S, Tekawa IS, Sadler M, Friedman GD. Health care use by frequent marijuana smokers who do not smoke tobacco. West J Med 1993; 158:596-601.

  93. Adams IB, Martin BR. Cannabis: Pharmacology and toxicology in animals and humans. Addiction 1996; 91:1585-614.

  94. Friedman H, Newton C, Klein TW. Microbial infections, immunomodulation, and drugs of abuse. Clin Microbiol Rev 2003; 16(Suppl 2):209-19.

  95. Zhu LX, Sharma S, Stolina M, Gardner B, Roth MD, Tashkin DP, et al. Delta-9 tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptormediated, cytokine-dependent pathway. J Immunology 2000; 165(Suppl 1):373- 80.

  96. Hanssen. Cannabinoids enhance susceptibility of immature brain to ethanol neurotoxicity. Ann Neurol 2008; 64(1):42-52.

  97. Novotny M, Lee ML, Bartle KD. A possible chemical basis for the higher mutagenicity of marihuana smoke as compared to tobacco smoke. Experientia 1976; 32: 280-2.

  98. Busch FW, Seid DA, Wei ET. Mutagenic activity of marihuana smokes condensates. Cancer Lett 1979; 6: 319-24.

  99. Wehner FC, Van Rensburg SJ, Theil PG. Mutagenic activity of marihuana and transkei tobacco smoke condensates in the Salmonella/microsome assay. Mutat Res 1980; 77: 135-42.

  100. Kolodny RC, Masters WH, Kolodner RM, Toro G. Depression of plasma testosterone levels after chronic intensive marihuana use. N Engl J Med 1974; 290: 872-4.

  101. Hollister, LE. Health aspects of cannabis. Pharmacol Rev 1986; 38:1-17.

  102. Zimmer L, Morgan JP. Marijuana Myths, Marijuana Facts. New York: Lindesmith Center, 1997.

  103. Lares A, Ochoa Y, Bolanos A, Aponte N, Montenegro M. Effects of the resin and smoke condensate of Cannabis sativa on the oestrus cycle of the rat. Bull Narc 1981; 33: 55-61.

  104. Sauer MA, Rifka SM, Hawks RL, Cutler GB, Loriaux DL. Marijuana: interaction with the estrogen receptor. J Pharmacol Exp Ther 1983; 224: 404-7.

  105. Lorenzo P, Ladero JM, Leza JC, Lizasoain I. Drogodependencias: farmacología, patología, psicología, legislación. 2ª edición, Madrid: Médica Panamericana; 2003. p. 288-90.

  106. Haney M, Ward AS, Comer SD, Wards AS, Foltin RW, Fischman MW. Abstinence symptoms following smoked marijuana in humans. Psychopharmacol 1999; 141:395-404.

  107. O’Brien, C. Adicción y abuso de drogas. En: Harman JG, Limbird LE, Goodman & Gilman A. Goodman y Gilman. Las bases farmacológicas de la terapéutica. 10ª. ed. México: McGraw-Hill Interamericana; 2002. p. 646.

  108. Abood ME, Martin BR. Neurobiology of marijuana abuse. Trends Pharmacol Sci 1992; 13: 201-7.

  109. Bass CE, Martin BR. Time course for the induction and maintenance of tolerance to delta-9-tetrahidrocannabinol in mice. Drug Alcohol Depend 2000; 60: 113-9.

  110. Rodriguez de Fonseca F, Gorriti MA, Fernandez- Ruiz JJ, Palomo T, Ramos JA. Downregulation of rat brain cannabinoid binding sites after chronic delta-9- tetrahydrocannabinol treatment. Pharmacol Biochem




2020     |     www.medigraphic.com